房地产行业 | 证券研究报告 — 行业周报 2024年4月9日 强于大市 房地产行业第 14 周周报（3 月 30 日-4 月 5 日） 本周新房成交环比转负、同比降幅持续收窄； 多地阶段性取消首套房贷利率下限 相关研究报告 《房地产2024年1-2月统计局数据点评：销售新开 新房成交面积环比由正转负，同比降幅收窄；二手房成交面积环比由正转负， 工降幅显著扩大，竣工增速如期下滑》（2024/03/22） 同比降幅扩大；土地市场环比量价齐升，溢价率环比上升。 《房地产行业2024年2月70个大中城市房价数据点 评：70城房价下行压力仍然较大，二手房房价下跌趋 核心观点 势放缓》（2024/03/16）  新房成交面积环比由正转负，同比降幅收窄。新房成交面积为235.0万平方米，环比 《淡季楼市地市成交低迷；房企现金流形势紧迫—房 下降43.1%，环比较上周下降了84.6个百分点，同比下降34.4%，同比降幅较上周缩 地产行业2024年2月月报》（2024/3/16） 小了6.8个百分点。一、二、三四线城市新房成交面积环比增速分别为-27.6%、-50.3%、 《房贷成本有望进一步下行；标本兼治化解房地产风 - ...

中银国际证券股份有限公司 具备证券投资咨询业务资格 宏观经济 证券分析师：朱启兵 (8610)66229359 Qibing.Zhu@bocichina.com 证券投资咨询业务证书编号：S1300516090001 证券分析师：周亚齐 yaqi.zhou@bocichina.com 证券投资咨询业务证书编号：S1300522090002 宏观经济 | 证券研究报告 — 总量月报 2024 年 4 月 9 日 海外宏观和大类资产月报 海外宏观概览 市场分析 … 主要海外资产观点…………………………………………………………………………………………………………………………… 12 "银证券 目 录 2024 年 4 月 9 日 2 海外宏观和大类资产月报 图表 1. 美国经济景气指数 Z-Score ...............................................................................4 图表 2. ISM 以及 Markit 制造业 PMI 均呈现趋势性触底回暖 ..................................5 图表 ...

| --- | --- | --- | --- | --- | |----------------------------------------|------------------------------------------------------|-----------------------------------|-------|---------------------------------------------------------------------------------------| | 证券研究报告 \n3 月金股组合 股票代码 | —— 晨会聚焦 | \n股票名称 | | 2024 年 3 月 18 日 \n中银晨会聚焦 -20240318 | | 601288.SH | | 农业银行 | | | | 600428.SH | | 中远海特 | | | | | | | ■ | 重点关注 | | 002372.SZ | | 伟星新材 | | | | 002409.SZ | | 雅克科技 天顺风能 | | 【宏观经济】 2 月金融数据点评 * 朱启兵 孙德基。 2 月份社会融资 ...

宏观经济 | 证券研究报告 — 总量周报 2024 年 4 月 7 日 大类资产配置顺序：股票>大宗>债券>货币。 ◼ 经济数据：无。 资产表现回顾 资产配置建议 | --- | --- | --- | --- | |----------|-------|--------------------------------------|----------| | 宏观经济 | | 本期观点 | 观点变化 | | 一个月内 | = | 关注两会后配套政策发布 | 不变 | | 三个月内 | = | 关注上半年财政措施落实情况 | 不变 | | 一年内 | - | 欧美经济下行趋势和全球局势变化 | 不变 | | 大类资产 | | 本期观点 | 观点变化 | | 股票 | + | 以万亿国债落地为代表的稳增长政策发力 | 超配 | | 债券 | = | 货币政策偏宽松压制收益率上行空间 | 标配 | | 货币 | - | 收益率将在 2% 上下波动 | 低配 | | 大宗商品 | + | 稳增长政策利好基建投资 | 超配 | | 外汇 | = | 中国经济基本面优势支撑汇率宽幅波动 | 标配 | 证券分析师：朱启兵 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the company's stock price will outperform the benchmark index by more than 20% over the next 6-12 months [9][23]. Core Insights - The company achieved a revenue of 3.999 billion RMB in 2023, representing a year-on-year growth of 5.79%. However, the net profit attributable to shareholders decreased by 6.55% to 619 million RMB, indicating some pressure on profitability [4][18]. - The company has adjusted its pharmaceutical sales structure from a "line-based" model to a "hospital-retail" model, which is expected to enhance sales capabilities and expand future growth opportunities [4][18]. - Increased investment in research and development (R&D) is noted, with R&D expenses reaching 401 million RMB in 2023, a 9.23% increase year-on-year. The company is advancing its pipeline, including the registration of its first Class 1 new drug, which is set to launch in March 2024 [4][18]. Financial Summary - The company reported a total revenue of 3.999 billion RMB for 2023, with a growth rate of 5.8%. The projected revenues for 2024, 2025, and 2026 are 4.388 billion RMB, 4.851 billion RMB, and 5.415 billion RMB, respectively, with expected growth rates of 9.7%, 10.5%, and 11.6% [19][20]. - The net profit for 2023 was 619 million RMB, with projections for 2024, 2025, and 2026 at 649 million RMB, 749 million RMB, and 889 million RMB, respectively, indicating a recovery in profitability in the coming years [19][20]. - The earnings per share (EPS) for 2023 was 0.72 RMB, with forecasts of 0.75 RMB, 0.87 RMB, and 1.03 RMB for the following years [19][20].

Investment Rating - The report maintains an "Accumulate" rating for the company [1][3]. Core Views - The company reported a net profit of 1.924 billion RMB for 2023, a decrease of 14.80% year-on-year, which aligns with expectations [3]. - The company's revenue for 2023 was 15.127 billion RMB, down 28.86% year-on-year, indicating a challenging market environment [3]. - New products, particularly advanced cathode materials, are expected to accelerate in volume, providing potential growth opportunities [3]. Financial Summary - The company achieved a revenue of 15.127 billion RMB in 2023, a decline of 28.86% compared to 2022 [4][5]. - The net profit for 2023 was 1.924 billion RMB, down 14.80% year-on-year [4][5]. - The earnings per share (EPS) for 2023 was 3.80 RMB, reflecting a decrease of 14.80% from the previous year [4][5]. - The projected EPS for 2024, 2025, and 2026 are 2.50 RMB, 2.77 RMB, and 2.97 RMB respectively, with corresponding price-to-earnings ratios of 16.9, 15.2, and 14.2 [4][5][8]. Market Performance - The company's stock price is currently at 42.10 RMB, with a market capitalization of approximately 21.32 billion RMB [1][2]. - Year-to-date performance shows an absolute increase of 11.5%, outperforming the Shenzhen Composite Index by 10.0% [2].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the company's stock price will outperform the benchmark index by more than 20% over the next 6-12 months [2][8]. Core Insights - The company achieved significant growth in 2023, with total revenue reaching 6.302 billion RMB, a year-on-year increase of 78.05%, and a net profit attributable to shareholders of 1.256 billion RMB, up 76.10% year-on-year. The company's platform strategy is showing initial success, supporting future growth [2][4]. - All business segments experienced rapid revenue growth, with solar equipment, lithium battery equipment, and semiconductor businesses generating revenues of 5.364 billion RMB, 347 million RMB, and 21 million RMB, respectively, reflecting growth rates of 79.15%, 165.13%, and 365.34% [2][4]. - The company demonstrated excellent cost control, maintaining a net profit margin of 19.91%, which is an increase of 0.28 percentage points year-on-year, despite a slight decline in overall gross margin to 36.55% [2][4]. Financial Performance Summary - In 2023, the company reported total revenue of 6,302.20 million RMB, with a gross profit margin of 36.55%, down 2.38 percentage points from the previous year. The net profit attributable to shareholders was 1,255.82 million RMB, reflecting a net profit margin of 19.91% [4][6]. - The company expects to achieve revenues of 8.749 billion RMB, 11.291 billion RMB, and 14.075 billion RMB for the years 2024, 2025, and 2026, respectively, with corresponding net profits of 1.735 billion RMB, 2.326 billion RMB, and 2.904 billion RMB [3][5]. - The report projects a PE ratio of 14.1, 10.6, and 8.4 for the years 2024, 2025, and 2026, respectively, indicating a favorable valuation outlook [3][5].

基础化工 | 证券研究报告 — 行业周报 2024年4月8日 强于大市 化工行业周报 20240407 国际油价上涨，萤石价格上涨 4 月份建议关注：1、大宗商品价格上行，关注大型能源央企及相关油服公司在新时代背景下的 改革改善与经营业绩提升；2、年报一季报超预期公司行情；3、下游催化较多，估值仍处相对 低位的半导体、OLED等电子材料公司；4、化纤、制冷剂、化肥等子行业的旺季及补库行情。 行业动态  本周（4.1-4.7）均价跟踪的101个化工品种中，共有43个品种价格上涨，27个品种价格下 跌，31个品种价格稳定。周均价涨幅居前的品种分别是煤焦油（山西）、氟化铝、NYMEX 天然气、二氯甲烷（华东）、WTI原油；而周均价跌幅居前的品种分别是醋酸乙烯（华东）、 液氨（河北新化）、甲基环硅氧烷、尿素、金属硅。  本周（4.1-4.7）国际油价持续上涨，WTI原油收于86.77美元/桶，收盘价周涨幅3.20%；布 伦特原油收于90.86美元/桶，收盘价周涨幅3.47%。宏观方面，中国和美国制造业指数显著 改善；3月中国制造业PMI为50.8%，比上月上升1.7个百分点，高于临界点。供给端，美 国的能源企业石 ...

基础化工 | 证券研究报告 — 调整盈利预测 2024年4月8日 002648.SZ 卫星化学 买入 归母净利润大幅增长，新项目增添新动能 原评级：买入 市场价格:人民币 19.01 2023年度公司实现营业收入414.87亿元，同比增长12.00%；归母净利润47.89亿元， 同比增长54.71%。其中，第四季度实现营收106.05亿元，同比增长14.37%，环比减 板 块评级:强于大市 少2.41%，归母净利润13.96亿元，同比增长2693.91%，环比减少10.02%。公司经 营业绩大幅增长，看好其轻烃产业链优势以及未来优质产能扩张，维持“买入”评级。 股价表现 支撑评级的要点  轻烃路线优势凸显，归母净利润大幅增长。2023年，在石化行业整体需求下滑、 22% 产品价格下降的背景下，公司依托轻烃一体化产业布局，营收和归母净利润同比 11% 均实现正增长。2023年公司销售毛利率19.84%，同比+3.32 pct，其中，功能化学 品、高分子新材料、新能源材料、其他业务的营收分别为212.89亿元、119.16亿 0% 元、4.65亿元、78.17亿元，同比分别+8.74%、+61.92%、+99. ...

基础化工 | 证券研究报告 — 调整盈利预测 2024 年 4 月 8 日 002407.SZ 增持 原评级：增持 市场价格:人民币 15.40 板块评级:强于大市 股价表现 (55%) (44%) (32%) (21%) (10%) 2% Apr-23May-23Jun-23Jul-23Aug-23Sep-23Oct-23Nov-23Dec-23Jan-24Feb-24Mar-24 | --- | --- | --- | --- | --- | |------------------------------------------|-------------------------|-----------------------------------|----------------------|---------------------------| | 多氟多 \n(%) \n绝对 \n相对深圳成指 | 今年 至今 \n3.6 \n2.1 | 深圳成指 \n1 个月 \n17.7 \n16.6 | 3 个月 \n3.5 \n1.2 | 12 个月 \n(53.9) \n(34.2) | | 发行股数 ...